Leukemia Medications

*generic version available

E experimental

Chemotherapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Chemotherapy	Multiple	Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.
Inqovi	decitabine/cedazuridine	Inqovi is a combination of two oral chemotherapy drugs, decitabine and cedazuridine, used for the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Onureg	azacitidine	Onureg (azacitidine) is a nucleoside analog approved for continued treatment of people with acute myeloid leukemia who achieved complete remission following induction chemotherapy.

Targeted Therapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Arzerra	ofatumumab	Arzerra is a monoclonal antibody approved for chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy.
Ayvakit	avapritinib	Ayvakit is a kinase inhibitor approved for the treatment of inoperable or metastatic gastrointestinal stromal tumor (GIST) with specific PDGFRA mutations and for advanced systemic mastocytosis.

DRUG	GENERIC NAME	DRUG INDICATION
Besponsa	inotuzuma ozogamicin	Besponsa is an antibody-drug conjugate approved for adults with B cell acute lymphoblastic leukemia that does not respond to prior treatment.
Blincyto	blinatumomab	Blincyto is a bispecific T-cell engager approved for adults and children with B cell acute lymphoblastic leukemia.
Bosulif	bosutinib	Bosulif is a kinase inhibitor approved for adults with newly diagnosed or previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.
Calquence	acalabrutinib	Calquence is a BTK kinase inhibitor approved for mantle cell lymphoma and as a first-line or subsequent treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Campath	alemtuzumab	Campath is a targeted therapy approved for people with B-cell chronic lymphocytic leukemia who were previously treated with other medications. It is no longer commercially available for leukemia, but has been rebranded as Lemtrada for multiple sclerosis.
Copiktra	duvelisib	Copiktra is a PI3K kinase inhibitor approved for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.
Elzonris	tagraxofusp-erzs	Elzonris is a CD123-directed toxin approved for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare bone marrow and blood disease that can evolve into leukemia.
Gazyva	obinutuzumab	Gazyva is a monoclonal antibody approved for follicular lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, in combination with chemotherapy.
Gleevec	imatinib	Gleevec, a kinase inhibitor, was one of the first targeted therapies for cancer treatment. It is approved for many indications including Philadelphia chromosome positive (Ph+) chronic myeloid leukemia and acute lymphoblastic leukemia, chronic eosinophilic leukemia, mastocytosis and gastrointestinal stromal tumor.

DRUG	GENERIC NAME	DRUG INDICATION
Iclusig	ponatinib	Iclusig is a kinase inhibitor approved for adults with chronic myeloid leukemia or acute lymphoblastic leukemia with specific characteristic who are resistant to or cannot use other kinase inhibitors.
Idhifa	enasidenib	Idhifa is an IDH2 inhibitor approved for adults with acute myeloid leukemia with IDH2 mutations that does not respond to prior treatment.
Imbruvica	ibrutinib	Imbruvica is a BTK kinase inhibitor approved for mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma and Waldenstrom macroglobulinemia. It is also used to treat graft-versus-host disease, which can occur after a stem cell transplant.
Lumoxiti	moxetumomab pasudotox	Lumoxiti is a CD22-directed toxin approved for adults with hairy cell leukemia that does not respond to prior treatment.
Mylotarg	gemtuzumab ozogamicin	Mylotarg is a CD33-directed antibody-drug conjugate approved for adults and children with newly diagnosed or relapsed or refractory acute myeloid leukemia.
Rituxan	rituxumab	Rituxan is a monoclonal antibody approved for follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy. Truxima and Ruxience are biosimilar medications.
Rydapt	midostaurin	Rydapt is a kinase inhibitor approved for adults with newly diagnosed acute myeloid leukemia with FLT3 mutations, and for mastocytosis or mast cell leukemia.
Sprycel	dasatinib	Sprycel is a kinas inhibitor approved for adults and children with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia or acute lymphoblastic leukemia.
Tasigna	nilotinib	Tasigna is a kinase inhibitor approved for newly diagnosed or previously Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

DRUG	GENERIC NAME	DRUG INDICATION
Tibsovo	ivosidenib	Tibsovo is an IDH1 inhibitor approved for adults with acute myeloid leukemia with IDH1 mutations that has relapsed or does not respond to prior treatment.
Venclexta	venetoclax	Venclexta is a BCL-2 inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in previously treated patients, first-line treatment of CLL or SLL in combination with Gazyva (obinutuzumab) and acute myeloid leukemia in patients who can't use intensive chemotherapy.
Xospata	gilteritinib	Xospata is a kinase inhibitor approved for treatment of adults with relapsed or refractory acute myeloid leukemia with an FLT3 mutation.
Zydelig	idelalisib	Zydelig is a PI3K kinase inhibitor approved for relapsed follicular lymphoma, relapsed chronic lymphocytic leukemia and relapsed small lymphocytic lymphoma.

DRUG Chemotherapy

GENERIC NAME Multiple

DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Inqovi

GENERIC NAME decitabine/cedazuridine

DRUG INDICATION

Inqovi is a combination of two oral chemotherapy drugs, decitabine and cedazuridine, used for the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.

DRUG Onureg

GENERIC NAME azacitidine

DRUG INDICATION

Onureg (azacitidine) is a nucleoside analog approved for continued treatment of people with acute myeloid leukemia who achieved complete remission following induction chemotherapy.

DRUG Arzerra

GENERIC NAME ofatumumab

DRUG INDICATION

Arzerra is a monoclonal antibody approved for chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy.

DRUG Ayvakit

GENERIC NAME avapritinib

DRUG INDICATION
Ayvakit is a kinase inhibitor approved for the treatment of inoperable or metastatic gastrointestinal stromal tumor (GIST) with specific PDGFRA mutations and for advanced systemic mastocytosis.

DRUG Besponsa

GENERIC NAME inotuzuma ozogamicin

DRUG INDICATION
Besponsa is an antibody-drug conjugate approved for adults with B cell acute lymphoblastic leukemia that does not respond to prior treatment.

DRUG Blincyto

GENERIC NAME blinatumomab

DRUG INDICATION
Blincyto is a bispecific T-cell engager approved for adults and children with B cell acute lymphoblastic leukemia.

DRUG Bosulif

GENERIC NAME bosutinib

DRUG INDICATION
Bosulif is a kinase inhibitor approved for adults with newly diagnosed or previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

DRUG Calquence

GENERIC NAME acalabrutinib

DRUG INDICATION
Calquence is a BTK kinase inhibitor approved for mantle cell lymphoma and as a first-line or subsequent treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

DRUG Campath

GENERIC NAME alemtuzumab

DRUG INDICATION
Campath is a targeted therapy approved for people with B-cell chronic lymphocytic leukemia who were previously treated with other medications. It is no longer commercially available for leukemia, but has been rebranded as Lemtrada for multiple sclerosis.

DRUG Copiktra

GENERIC NAME duvelisib

DRUG INDICATION
Copiktra is a PI3K kinase inhibitor approved for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.

DRUG Elzonris

GENERIC NAME tagraxofusp-erzs

DRUG Elzonris

DRUG INDICATION
Elzonris is a CD123-directed toxin approved for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare bone marrow and blood disease that can evolve into leukemia.

DRUG Gazyva

GENERIC NAME obinutuzumab

DRUG INDICATION
Gazyva is a monoclonal antibody approved for follicular lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, in combination with chemotherapy.

DRUG Gleevec

GENERIC NAME imatinib

DRUG INDICATION
Gleevec, a kinase inhibitor, was one of the first targeted therapies for cancer treatment. It is approved for many indications including Philadelphia chromosome positive (Ph+) chronic myeloid leukemia and acute lymphoblastic leukemia, chronic eosinophilic leukemia, mastocytosis and gastrointestinal stromal tumor.

DRUG Iclusig

GENERIC NAME ponatinib

DRUG INDICATION
Iclusig is a kinase inhibitor approved for adults with chronic myeloid leukemia or acute lymphoblastic leukemia with specific characteristic who are resistant to or cannot use other kinase inhibitors.

DRUG Idhifa

GENERIC NAME enasidenib

DRUG INDICATION
Idhifa is an IDH2 inhibitor approved for adults with acute myeloid leukemia with IDH2 mutations that does not respond to prior treatment.

DRUG Imbruvica

GENERIC NAME ibrutinib

DRUG INDICATION
Imbruvica is a BTK kinase inhibitor approved for mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma and Waldenstrom macroglobulinemia. It is also used to treat graft-versus-host disease, which can occur after a stem cell transplant.

DRUG Lumoxiti

GENERIC NAME moxetumomab pasudotox

DRUG INDICATION
Lumoxiti is a CD22-directed toxin approved for adults with hairy cell leukemia that does not respond to prior treatment.

DRUG Mylotarg

GENERIC NAME gemtuzumab ozogamicin

DRUG INDICATION
Mylotarg is a CD33-directed antibody-drug conjugate approved for adults and children with newly diagnosed or relapsed or refractory acute myeloid leukemia.

DRUG Rituxan

GENERIC NAME rituxumab

DRUG INDICATION
Rituxan is a monoclonal antibody approved for follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy. Truxima and Ruxience are biosimilar medications.

DRUG Rydapt

GENERIC NAME midostaurin

DRUG INDICATION
Rydapt is a kinase inhibitor approved for adults with newly diagnosed acute myeloid leukemia with FLT3 mutations, and for mastocytosis or mast cell leukemia.

DRUG Sprycel

GENERIC NAME dasatinib

DRUG INDICATION
Sprycel is a kinas inhibitor approved for adults and children with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia or acute lymphoblastic leukemia.

DRUG Tasigna

GENERIC NAME nilotinib

DRUG INDICATION
Tasigna is a kinase inhibitor approved for newly diagnosed or previously Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

DRUG Tibsovo

GENERIC NAME ivosidenib

DRUG INDICATION
Tibsovo is an IDH1 inhibitor approved for adults with acute myeloid leukemia with IDH1 mutations that has relapsed or does not respond to prior treatment.

DRUG Venclexta

GENERIC NAME venetoclax

DRUG INDICATION
Venclexta is a BCL-2 inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in previously treated patients, first-line treatment of CLL or SLL in combination with Gazyva (obinutuzumab) and acute myeloid leukemia in patients who can't use intensive chemotherapy.

DRUG Xospata

GENERIC NAME gilteritinib

DRUG INDICATION
Xospata is a kinase inhibitor approved for treatment of adults with relapsed or refractory acute myeloid leukemia with an FLT3 mutation.

DRUG Zydelig

GENERIC NAME idelalisib

DRUG INDICATION
Zydelig is a PI3K kinase inhibitor approved for relapsed follicular lymphoma, relapsed chronic lymphocytic leukemia and relapsed small lymphocytic lymphoma.

© 2026 Smart + Strong All Rights Reserved.